HALDA Therapeutics develops RIPTAC therapeutics, which use protein-protein interactions to selectively target and kill cancer cells.

HALDA Therapeutics

Halda is inventing novel precision medicines for oncology.  Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer.  This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines.  Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.

6 Dimensions Capital

WuXi Healthcare Ventures

Canaan Partners

Connecticut Innovations

Elm Street Ventures

Access Biotechnology

Halda Therapeutics

Cloudflare Hosting

Person Schema

Gravatar Profiles

Associate Director - Chemistry

James Mousseau

Finance and Administration

Jessica Tonini

Head of in-Vivo Operations

Kelli Jones

Associate Director, Biology

Louise Giffin

Operations

Allison Denny

Office Manager

Stephanie Scarcella

Associate Scientist

Abigail Hundt

Engineering

David Puleo

Marco Garcia ,BA

Arjun Goyal

Craig M. Crews

Founder

Timothy Shannon

President, Chief Executive Officer & Board Member

New England Biotechnology Companies

Therapeutics Companies With Less Than $10M in Revenue (Top 10K)

Connecticut Early Stage Companies With More Than $1M in Revenue

Venture Debt Funded Companies

Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

Series B - Halda Therapeutics

Venture Round - Halda Therapeutics

Series A - Halda Therapeutics

Computer and Software Services and Scientific Services

New Haven

Connecticut

United States

North America

The Week’s 10 Biggest Funding Rounds: Cybersecurity Leads With Kiteworks’ Nearly Half-Billion-Dollar Deal

Halda Therapeutics Raises $126 Million (Series B) To Advance Cancer Therapies

Halda Therapeutics Inks $126M Series B Extension

Halda Therapeutics describes new heterobifunctional compounds for cancer

Halda Therapeutics presents new PROTACs for cancer

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

Halda Therapeutics discloses new PROTACs for cancer

A class of heterobifunctional small molecules designed to treat cancer by inducing selective cancer cell death through a novel 'hold and kill' mechanism.

A class of heterobifunctional small molecules designed to selectively kill cancer cells by forming a trimeric complex with a tumor-specific protein and an essential protein, leading to cancer cell death.

An orally administered RIPTAC therapeutic targeting prostate cancer by leveraging androgen receptor expression to overcome drug resistance.

Bangladesh

Asia

Mexico

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 13, 2024 1:03 PM	f5765835
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	06d2de6e
crunchbase profile	general	Nov 25, 2024 11:08 AM	2feb0e0d
li profile	general	Aug 13, 2024 1:03 PM	5c1c4bfc
translate crunchbase fundingrounds	general	Nov 25, 2024 2:25 PM	6e57c1cf
peers	general	Aug 13, 2024 1:03 PM	760afd9b
news basic	general	Aug 13, 2024 1:03 PM	61bbec38
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:HALDATHERAPEUTICS

HALDA Therapeutics